ArticleJournal of the National Cancer Institute2022

Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.

Lillian Y Lai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.